PEAK6
REGN icon

PEAK6’s Regeneron Pharmaceuticals REGN Stock Holding History

PEAK6’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$464K Buy
600
+500
+500% +$383K ﹤0.01% 2006
2025
Q4 		$77.2K Sell
100
-26,400
-100% -$17.9M ﹤0.01% 2550
2025
Q3 		$14.9M Sell
26,500
-54,500
-67% -$30.8M 0.02% 527
2025
Q2 		$42.5M Buy
+81,000
New +$45.2M 0.08% 208
2025
Q1 		– Sell
-10,400
Closed -$7.41M – 3514
2024
Q4 		$7.41M Buy
+10,400
New +$8.73M 0.02% 706

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

PEAK6's REGN Position: Q1 2026 in Review

PEAK6 increased its Regeneron Pharmaceuticals (REGN) stake by 98,400% in Q1 2026, buying an estimated $2.26M and bringing the position to 2,955 shares worth $2.28M. The position accounts for 0.01% of the portfolio, ranked #1311.

PEAK6 first reported a position in REGN in Q4 2024 and has held it in 5 quarters since. The position peaked at $19.5M in Q2 2025. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • PEAK6 held 2,955 shares of Regeneron Pharmaceuticals worth $2.28M as of Q1 2026.
  • PEAK6 bought 2,952 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $2.26M.
  • Regeneron Pharmaceuticals made up 0.01% of PEAK6's portfolio in Q1 2026, its #1311 holding.
  • PEAK6 first reported a position in Regeneron Pharmaceuticals in Q4 2024 and has held it in 5 quarters since.
  • PEAK6's Regeneron Pharmaceuticals position peaked at $19.5M in Q2 2025.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on PEAK6's 13F filing for Q1 2026, filed 14 May 2026.